Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 6, 2025
RPM Healthcare’s Study on Remote Patient Monitoring and Stage 2 Hypertension Accepted for Publication in AJMC
EIN Presswire
·
March 6, 2025
ST. PETERSBURG, FL, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- RPM Healthcare is proud to announce that our manuscript, “Effect of Remote Patient Monitoring on Stage 2 Hypertension,” has been officially accepted for publication in The American …
New Book Release: Embracing Fitness as You Age – A Guide to Maintaining a Healthy and Active Lifestyle Beyond Sixty
EIN Presswire
·
March 6, 2025
Dr. Torres has released his latest book, Embracing Fitness as You Age: Maintaining a Healthy and Active Lifestyle Beyond Sixty, which is now available on Amazon CLEARWATER, FL, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Dr. Francisco M. Torres, …
CONFIDENCE MATTERS! ONE-MAN SHOW STARRING DW STARR PREMIERES MARCH 22ND AT ORLANDO FAMILY STAGE
EIN Presswire
·
March 6, 2025
CONFIDENCE MATTERS! is an interactive, fun, energetic, and mind expanding theatrical show written especially for youth featuring superhero Confidence Crusader. ORLANDO, FL, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- CONFIDENCE MATTERS! is a one- …
A Safe Haven for Newborns, The Safety Net for Mothers in Crisis
EIN Presswire
·
March 6, 2025
Together We Can Make a Difference by Providing the Help They Need MIAMI, FL, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- The Gloria M. Silverio Foundation, 501 C3, d/b/a/ A Safe Haven for Newborns, is the safety net a pregnant teen or woman needs …
Mesoblast Added to S&P/ASX 200 INDEX
GlobeNewswire
·
March 6, 2025
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S…
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
GlobeNewswire
·
March 6, 2025
MISSISSAUGA, Ontario, March 06, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2024 on Thursday, March 13, 2025 after market …
President & CEO Letter to Shareholders
GlobeNewswire
·
March 6, 2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 06, 2025 (GLOBE NEWSWIRE) -- Dear Nova Leap Health Corp. (“Nova Leap” or the “Company”) Shareholders: All amounts are in United States …
Nova Leap Health Corp. Posts Fourth Quarter and 2024 Annual Financial Results Including Record Adjusted EBITDA for 2nd Consecutive Year
GlobeNewswire
·
March 6, 2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 06, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is …
Tarsus to Participate in Upcoming Investor Conference
GlobeNewswire
·
March 6, 2025
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11th, at 8:00 a.m …
Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting
GlobeNewswire
·
March 6, 2025
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San …
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 6, 2025
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trial Severe flu season enables potential mid-year assessment of efficacy Closed $105.0 million financing with new and existing investors Significantly expanded equity research coverage SAN DIEGO, …
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
GlobeNewswire
·
March 6, 2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 …
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
·
March 6, 2025
- Duchenne: Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated …
CooperCompanies Announces First Quarter 2025 Results
GlobeNewswire
·
March 6, 2025
SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964 …
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
GlobeNewswire
·
March 6, 2025
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from …
New study links sports gambling with alcohol-related risks over time
GlobeNewswire
·
March 6, 2025
Las Vegas, NV 89109, March 06, 2025 (GLOBE NEWSWIRE) -- A new longitudinal study published in JAMA Psychiatry finds that sports gambling frequency and alcohol-related problems are strongly associated over time, reinforcing concerns about the potential …
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 6, 2025
- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY® Interferon-alpha 2b) Phase 1a translational …
TerrAscend Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 6, 2025
Fourth Quarter Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024 Fourth Quarter Gross Profit Margin of 50.2%, up 140 basis points from 48.8% in the third quarter of 2024 Full Year 2024 Net Cash provided by continuing …
Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results
GlobeNewswire
·
March 6, 2025
– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 – – VCN-01 development bolstered by FDA award of Fast Track designation for the treatment of PDAC and …
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 6, 2025
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differentiation over …